Bilaketaren emaitzak

Discovery of NCT-501, a Potent and Selective Theophylline-Based Inhibitor of Aldehyde Dehydrogenase 1A1 (ALDH1A1) nork Shyh‐Ming Yang, Adam Yasgar, Bettina Miller, Madhu Lal‐Nag, Kyle R. Brimacombe, Xin Hu, Hongmao Sun, Amy Wang, Xin Xu, Kimloan Nguyen, Udo Oppermann, Marc Ferrer, Vasilis Vasiliou, Anton Simeonov, Ajit Jadhav, David J. Maloney

Testu osoa

Drug Delivery Approaches in Addressing Clinical Pharmacology-Related Issues: Opportunities and Challenges nork Hong Wen, Huijeong Jung, Xuhong Li

Testu osoa Testu osoa

New paradigms in GPCR drug discovery nork Kenneth A. Jacobson

Testu osoa

Physiologically Based Pharmacokinetics Is Impacting Drug Development and Regulatory Decision Making nork Malcolm Rowland, LJ Lesko, Amin Rostami‐Hodjegan

Testu osoa Testu osoa

Projecting human pharmacokinetics of monoclonal antibodies from nonclinical data: comparative evaluation of prediction approaches in early drug development nork Jing Wang, Suhasini Iyer, Paul J. Fielder, John D. Davis, Rong Deng

Testu osoa Testu osoa

Molecular docking studies of anti-cancerous candidates in Hippophae rhamnoides and Hippophae salicifolia nork Talambedu Usha, Kumar Sushil, Arvind Kumar, Karthik Mahesh, Manoj DA, Faizan Syed, Arvind Kumar Goyal, HP Prashanth Kumar, Veena Pande

Testu osoa

Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp nork Khalid O. Alfarouk, C C Stock, Sophie Taylor, Megan Walsh, Abdel Khalig Muddathir, Daniel Verduzco, Adil H. H. Bashir, Osama Y Mohammed, Gamal Osman Elhassan, Salvador Harguindey, Stephan J. Reshkin, Muntaser E. Ibrahim, Cyril Rauch

Testu osoa Testu osoa

Modeling of interactions between xenobiotics and cytochrome P450 (CYP) enzymes nork Hannu Raunio, Mira Kuusisto, Risto O. Juvonen, Olli T. Pentikäinen

Testu osoa Testu osoa

Synthesis and potential antitumor activity of 7-(4-substituted piperazin-1-yl)-4-oxoquinolines based on ciprofloxacin and norfloxacin scaffolds: <i>in silico</i> studies nork Alaa A.‐M. Abdel‐Aziz, Adel S. El‐Azab, Amer M. Alanazi, Yousif A. Asiri, Ibrahim A. Al-Suwaidan, Azza R. Maarouf, Rezk R. Ayyad, Taghreed Z. Shawer

Testu osoa Testu osoa

Aminopyrazolo[1,5-a]pyrimidines as potential inhibitors of Mycobacterium tuberculosis: Structure activity relationships and ADME characterization nork Candice Soares de Melo, Tzu‐Shean Feng, Renier van der Westhuyzen, Richard K. Gessner, Leslie J. Street, Garreth L. Morgans, Digby F. Warner, A. Moosa, Krupa Naran, Nina Lawrence, Helena I. Boshoff, Clifton E. Barry, C. John Harris, Richard K. Gordon, Kelly Chibale

Testu osoa Testu osoa

Assessment of algorithms for predicting drug–drug interactions via inhibition mechanisms: comparison of dynamic and static models nork Eleanor J. Guest, Karen Rowland Yeo, Amin Rostami‐Hodjegan, Geoffrey T. Tucker, J. Brian Houston, Aleksandra Galetin

Testu osoa Testu osoa

The 8-Pyrrole-Benzothiazinones Are Noncovalent Inhibitors of DprE1 from Mycobacterium tuberculosis nork Vadim Makarov, João Neres, Ruben C. Hartkoorn, O. B. Ryabova, Elena Kazakova, Michal Šarkan, Stanislav Huszár, Jérémie Piton, Gaëlle S. Kolly, Anthony Vocat, Trent Conroy, Katarı́na Mikušová, Stewart T. Cole

Testu osoa Testu osoa

Discovery and Cardioprotective Effects of the First Non-Peptide Agonists of the G Protein-Coupled Prokineticin Receptor-1 nork Adeline Gasser, Simone Brogi, Kyoji Urayama, Toshishide Nishi, Hitoshi Kurose, Andrea Tafi, Nigel Ribeiro, Laurent Désaubry, Canan G. Nebigil

Testu osoa Testu osoa

One Scaffold, Three Binding Modes: Novel and Selective Pteridine Reductase 1 Inhibitors Derived from Fragment Hits Discovered by Virtual Screening nork Chidochangu P. Mpamhanga, Daniel Spinks, L.B. Tulloch, Emma Shanks, David A. Robinson, Iain T. Collie, Alan H. Fairlamb, Paul G. Wyatt, Julie A. Frearson, William N. Hunter, Ian H. Gilbert, Ruth Brenk

Testu osoa Testu osoa

Case Studies for Practical Food Effect Assessments across BCS/BDDCS Class Compounds using In Silico, In Vitro, and Preclinical In Vivo Data nork Tycho Heimbach, Binfeng Xia, Tsu‐Han Lin, Handan He

Testu osoa

Synthesis and Structure–Activity Relationship Studies of 4-((2-Hydroxy-3-methoxybenzyl)amino)benzenesulfonamide Derivatives as Potent and Selective Inhibitors of 12-Lipoxygenase nork Diane K. Luci, J. Brian Jameson, Adam Yasgar, Giovanni Diaz, Netra Joshi, Auric Kantz, Kate Markham, Steve Perry, Norine Kuhn, Jennifer Yeung, Edward H. Kerns, Lena Schultz, Michael Holinstat, Jerry L. Nadler, David Taylor, Ajit Jadhav, Anton Simeonov, Theodore R. Holman, David J. Maloney

Testu osoa

Advent of Imidazo[1,2-<i>a</i>]pyridine-3-carboxamides with Potent Multi- and Extended Drug Resistant Antituberculosis Activity nork Garrett C. Moraski, Lowell D. Markley, Philip A. Hipskind, Helena I. Boshoff, Sang‐Hyun Cho, Scott G. Franzblau, Marvin J. Miller

Testu osoa

Identification of PPARgamma Partial Agonists of Natural Origin (I): Development of a Virtual Screening Procedure and In Vitro Validation nork Laura Guasch, Esther Sala, Anna Castell‐Auví, Lídia Cedó, Klaus R. Liedl, Gerhard Wolber, Markus Muehlbacher, Miquel Mulero, Montserrat Pinent, Anna Ardèvol, Cristina Valls, Gerard Pujadas, Santiago Garcı́a-Vallvé

Testu osoa Testu osoa

Design Novel Dual Agonists for Treating Type-2 Diabetes by Targeting Peroxisome Proliferator-Activated Receptors with Core Hopping Approach nork Ying Ma, Shu‐Qing Wang, Weiren Xu, Run‐Ling Wang, Kuo‐Chen Chou

Testu osoa Testu osoa

Analysis of Global and Absorption, Distribution, Metabolism, and Elimination Gene Expression in the Progressive Stages of Human Nonalcoholic Fatty Liver Disease nork April D. Lake, Petr Novák, Craig D. Fisher, Jonathan P. Jackson, Rhiannon N. Hardwick, Dean Billheimer, Walter T. Klimecki, Nathan J. Cherrington

Testu osoa